Product Information
IMITREX 6 MG/0.5 ML PEN INJECT is a brand product labeled by GlaxoSmithKline LLC, priced at $460.0543 per ML under NDC 00173047900. Its NADAC has been published 412 times since Nov 28, 2013.
FDA first approved this application on Dec 28, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the sumatriptan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/.5mL
Manufacturer
GlaxoSmithKline LLCNDC
00173047900
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA020080FDA Approved
12/28/1992
TE Code
AB
On Market Since
1/23/1997
Pharmacological Classes
Price Statistics
The NADAC for IMITREX 6 MG/0.5 ML PEN INJECT has been published 412 times since Nov 28, 2013, and over the history we have for it it has risen 126.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $460.0543 per ML |
|---|---|
| All-time high | $462.7350 (Jun 11, 2025) |
| All-time low | $203.1120 (Nov 28, 2013) |
| 52-week high | $462.6322 |
| 52-week low | $460.0543 |
| Median price | $365.2378 |
| Average price | $359.8512 |
| Largest weekly change | +19.7% (May 22, 2024) |
| Weeks tracked | 412 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMITREX 6 MG/0.5 ML PEN INJECT?
The current National Average Drug Acquisition Cost (NADAC) for IMITREX 6 MG/0.5 ML PEN INJECT, manufactured by GlaxoSmithKline LLC, is $460.0543 per ML (NDC 00173047900), effective Sep 30, 2026.
How has the price of IMITREX 6 MG/0.5 ML PEN INJECT changed over time?
Over the history we have for it, the NADAC for IMITREX 6 MG/0.5 ML PEN INJECT has risen 126.5%. It has been tracked across 412 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IMITREX 6 MG/0.5 ML PEN INJECT?
Since Nov 28, 2013, the NADAC for IMITREX 6 MG/0.5 ML PEN INJECT has ranged from a low of $203.1120 (Nov 28, 2013) to a high of $462.7350 (Jun 11, 2025), with a median of $365.2378 per ML.
Are there cheaper alternatives to IMITREX 6 MG/0.5 ML PEN INJECT?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUMATRIPTAN 6 MG/0.5 ML VIAL, is $14.9345 per ML — about 97% below IMITREX 6 MG/0.5 ML PEN INJECT.
Who manufactures IMITREX 6 MG/0.5 ML PEN INJECT?
IMITREX 6 MG/0.5 ML PEN INJECT (NDC 00173047900) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.